ArticleTrials2025
The Liver Care Trial: screening for liver disease in individuals attending treatment for alcohol use disorder-study protocol for a randomized controlled study.
Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05855031 (The Liver Care Trial), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Liver Care Trial: Screening for Liver Disease in Individuals Attending Treatment for Alcohol Use Disorder - a Randomized Controlled Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundEarly diagnosis of alcohol-related liver disease (ALD) can improve survival if it leads to alcohol abstention or very light consumption. It is possible to screen for liver fibrosis, an asymptomatic condition of ALD that can lead to cirrhosis, by an easy and non-invasive approach called transient elastography. It has not yet been established whether screening for liver fibrosis reduces alcohol consumption among individuals with alcohol use disorders compared to standard treatment. In addition, it is important to address whether receiving a screening result indicating no ALD could lead to increased alcohol consumption (the certificate-of-health effect). This paper describes a study protocol aiming to evaluate alcohol drinking outcomes after screening for liver fibrosis among individuals receiving community-based treatment for alcohol use disorder.
methodsThe study follows a randomized, controlled trial design (RCT) with concealed allocation in a 2:1 ratio to the intervention group or the control group. Blinded outcome assessments will be conducted for both parallel groups. A total of 408 participants will be randomized to receive both transient elastography and blood tests (intervention group, n = 272) or standard of care consisting of a blood test (control group, n = 136). Participants are adults receiving outpatient treatment for alcohol use disorder at three specialized centres in Denmark with no known liver disease. The primary outcome is abstinence or light consumption (≤ 10 units/week, 1 unit = 12 g alcohol) throughout the last 30 days, evaluated 6 months after randomization using the validated timeline follow-back method, supplemented by review of electronic health records. Secondary outcomes include quality of life and motivation to reduce alcohol intake. Qualitative studies will explore emotional impacts of screening on participants' and health professionals' barriers to the implementation of screening. DISCUSSION: This study has the potential to offer important insights into the effect of screening for liver fibrosis on alcohol consumption among individuals who are attending treatment for alcohol use disorder. Furthermore, the study will provide insights into user and health professionals' experiences related to screening. Findings may have implications for the implementation of non-invasive screening for chronic liver disease in individuals receiving alcohol use disorder treatment.
trial registrationClinicalTrials.gov NCT05855031. Registered on the 20th of April 2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.